Last Update: Jun 01, 2026
Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)
ClinicalTrials.gov Identifier:
NCT07156149
Novartis Reference Number:CLNP023B11401
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

C3 Glomerulopathy
Recruiting
50
Sep 17, 2025
Jun 30, 2028
All
0 Years - 100 Years (Child, Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

* All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).

Exclusion Criteria:

* Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

Novartis Investigative Site

Recruiting

Fuchū,Tokyo,1838561,Japan

Novartis Investigative Site

Recruiting

Shinjuku Ku,Tokyo,1628666,Japan

Novartis Investigative Site

Recruiting

Shimajiri-Gun,Okinawa,901-1303,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Fukuoka,8028555,Japan

Novartis Investigative Site

Recruiting

Nagasaki,Nagasaki,852-8501,Japan

Novartis Investigative Site

Recruiting

Shizuoka,Shizuoka,420-8527,Japan

Novartis Investigative Site

Recruiting

Ishikawa,9208641,Japan

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+81337978748

Novartis Pharmaceuticals

-